ELOX — Eloxx Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Eloxx Pharmaceuticals Announces Submission Of Investigational New Drug Application For Zkn-013
Eloxx Pharmaceuticals Inc expected to post a loss of $2.97 a share - Earnings Preview
Brief: Eloxx Pharmaceuticals Announces Initiation Of Phase 2 Clinical Study Evaluating Elx-02 For Treatment Of Alport Syndrome With First Patient Dosed
Brief: Eloxx Pharmaceuticals Announces First Patients Enrolled In Phase 2 Clinical Study Evaluating Elx-02 For The Treatment Of Alport Syndrome
Eloxx Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Eloxx Pharmaceuticals Inc Reports Q3 Loss Per Share Of $0.09
Eloxx Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Eloxx Pharmaceuticals Opens Clinical Trial Sites For Mid-Stage Study of Alport Syndrome Therapy
Brief: Eloxx Pharmaceuticals Says Received Notice Of Delisting From Nasdaq
U.S. STOCKS ON THE MOVE-AST SpaceMobile, Third Harmonic Bio, BrainStorm
U.S. STOCKS ON THE MOVE-HeartBeam, Duckhorn Portfolio, Danaher
U.S. STOCKS ON THE MOVE-Adobe, Netflix, FTC Solar
Eloxx Pharmaceuticals slumps as cystic fibrosis drug fails mid-stage study
Eloxx Pharma tanks after mid-stage trial of cystic fibrosis treatment fails
Brief: Eloxx Pharmaceuticals Reports Topline Results From Phase 2 Combination Clinical Trial Of ELX-02 In Class 1 Cystic Fibrosis (CF) Patients
Eloxx Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Eloxx Pharmaceuticals Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Eloxx Pharmaceuticals Announces Changes To Board Of Directors
U.S. RESEARCH ROUNDUP-Eli Lilly, Gilead Sciences, Upwork